Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.39 |
| ▸ | C5 | P01031 | 1/20 | 0.39 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.38 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6567930 | 0.95 | MEN1 (0.43) | NAMPTMCHR1MEN1KMT2ALMNA | |
| SCHEMBL6566966 | 0.87 | TP53 (0.43) | MEN1KMT2ALMNASMN1; SMN2NPC1 | |
| SCHEMBL6567065 | 0.84 | CASR (0.43) | NAMPTMCHR1MEN1KMT2ALMNA | |
| SCHEMBL6566617 | 0.82 | MAPK1 (0.47) | NAMPTMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL6566704 | 0.82 | MCHR1 (0.43) | MCHR1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL6567858 | 0.82 | LIMK2 (0.44) | MEN1KMT2A | |
| SCHEMBL6565928 | 0.81 | MCHR1 (0.46) | MCHR1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL6564738 | 0.80 | CASR (0.44) | NAMPTMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL6565854 | 0.79 | KMT2A (0.46) | MEN1KMT2ALMNASMN1; SMN2NPC1 | |
| SCHEMBL6564786 | 0.79 | KMT2A (0.61) | MEN1KMT2ALMNASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1437344-A1 | BENZENE DERIVATIVES,PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | HRH4, HRH2, HRH1 | NAMPT 3240/4885MCHR1 382/4885MEN1 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.